3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
4
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Carcinoma, Squamous Cell
1
Anemia, Refractory, with Excess of Blasts
1
Allogeneic Stem Cell Transplantation
1
Interventions
Cisplatin
9
pembrolizumab
7
Radiosurgery
6
Gemcitabine
6
Paclitaxel
5
Dexamethasone
5
Taxes
4
Carboplatin
4
trametinib
3
ibrutinib
3
Surveys and Questionnaires
3
Standard of Care
3
Radiotherapy
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Lenalidomide
3
Fluorouracil
3
Erlotinib Hydrochloride
3
Blood Specimen Collection
3
Ascorbic Acid
3
venetoclax
2
veliparib
2
tocilizumab
2
pazopanib
2
obinutuzumab
2
naquotinib
2
lenvatinib
2
fludarabine
2
enzalutamide
2
Vemurafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Neoplasms
×
decitabine and cedazuridine drug combination
×
Clear all
NCT06351306
2025-03-24
DEC-C and Thioguanine for R/R AML
Columbia University
Phase 2
Withdrawn